Hessian Labs
Hessian Labs develops non-invasive, platelet-based proteomic diagnostics for cancer. The organization combines platelet proteomics, assay development, and an AI-enabled molecular informatics platform to discover and translate protein biomarkers into clinical tests for early detection, therapy monitoring, and multi-cancer screening. The company maintains a research publication record and a patent portfolio and is developing tests for prostate and breast cancer and a multi-cancer screening application.
Industries
Nr. of Employees
small (1-50)
Products
Platelet-proteomics prostate cancer detection test
A blood-based proteomic assay designed to indicate whether prostate cancer is likely to be present and to reduce unnecessary biopsies.
Platelet-proteomics prostate cancer monitoring test
A blood-based assay focused on identifying aggressive prostate cancer to inform whether urgent treatment is needed or active surveillance is appropriate.
Platelet-proteomics breast cancer diagnostic and monitoring tests
A suite of blood-based assays intended to classify breast lesions (invasive vs non-invasive), detect progression in genetically at-risk individuals, and monitor therapy response.
Platelet-proteomics multi-cancer screening test (development)
A multi-cancer blood screening application under development using platelet proteomic signatures to detect multiple organ-specific cancers.
Platelet-proteomics prostate cancer detection test
A blood-based proteomic assay designed to indicate whether prostate cancer is likely to be present and to reduce unnecessary biopsies.
Platelet-proteomics prostate cancer monitoring test
A blood-based assay focused on identifying aggressive prostate cancer to inform whether urgent treatment is needed or active surveillance is appropriate.
Platelet-proteomics breast cancer diagnostic and monitoring tests
A suite of blood-based assays intended to classify breast lesions (invasive vs non-invasive), detect progression in genetically at-risk individuals, and monitor therapy response.
Platelet-proteomics multi-cancer screening test (development)
A multi-cancer blood screening application under development using platelet proteomic signatures to detect multiple organ-specific cancers.
Expertise Areas
- Platelet proteomics
- Proteomic biomarker discovery and validation
- Clinical diagnostic test development
- AI-enabled molecular informatics
Key Technologies
- Platelet proteomics
- Proteomic assays
- AI-enabled molecular informatics
- Blood-based biomarker assays
News & Updates
Event coverage item listed in company journal.
Collection of media and historical presentations related to company scientific leadership.
Journal entry noting the CEO briefed the White House and a linked video and press release are provided.
Company CEO participated in a Cancer Moonshot press conference and briefed the White House (press release and video referenced).
Event coverage item listed in company journal.
Collection of media and historical presentations related to company scientific leadership.
Journal entry noting the CEO briefed the White House and a linked video and press release are provided.
Company CEO participated in a Cancer Moonshot press conference and briefed the White House (press release and video referenced).